The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | ALK-positive NSCLC: CNS progression

Name: ALK-positive NSCLC: CNS progression
Uploaded: 2019-09-30T00:00:00Z
Duration: 1 min 40 s
Description: Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, discusses the risk of CNS progression in patients with ALK-positive metastatic Non-Small cell lung cancer (NSCLC), and how we can determine and reduce the risk. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sanjay Popat • 30 Sep 2019

ESMO 2019

Lung Cancer Non-Small Cell Lung Cancer Crizotinib Lorlatinib

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, discusses the risk of CNS progression in patients with ALK-positive metastatic Non-Small cell lung cancer (NSCLC), and how we can determine and reduce the risk. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.